- ROUNDTABLE: Pharmacy’s future in sync with technology
- FDA advisory panel to consider OTC status of NSAIDs
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- Federal government must find alternatives to rescheduling hydrocodone combination drugs
TITUSVILLE, N.J. — The Food and Drug Administration has approved an update to the label of a Johnson & Johnson drug for HIV, the company said Monday.
Tibotec Therapeutics, a subsidiary of J&J, said the FDA approved a 200-mg formulation of Intelence (etravirine) for treating HIV in patients who have taken previous treatments and whose virus has become resistant to antiretroviral drugs.
The recommended dosage of the drug is either 200 mg or two 100-mg tablets; the 100-mg tablets will remain available on the market, Tibotec said. The company expected to launch the 200-mg formulation later this month.